Integrating Bulk and Single-Cell RNA Sequencing Reveals Heterogeneity, Tumor Microenvironment, and Immunotherapeutic Efficacy Based on Sialylation-Related Genes in Bladder Cancer
Zhiyong Tan,Xiaorong Chen,Jieming Zuo,Shi Fu,Jiansong Wang,Haifeng Wang
DOI: https://doi.org/10.2147/jir.s418433
IF: 4.5
2023-08-15
Journal of Inflammation Research
Abstract:Zhiyong Tan, 1– 3, &ast Xiaorong Chen, 4, &ast Jieming Zuo, 1– 3, &ast Shi Fu, 1– 3, &ast Jiansong Wang, 1– 3 Haifeng Wang 1– 3 1 Department of Urology, the Second Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, People's Republic of China; 2 Urological Disease Clinical Medical Center of Yunnan Province, the Second Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, People's Republic of China; 3 Scientific and Technological Innovation Team of Basic and Clinical Research of Bladder Cancer in Yunnan Universities, the Second Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, People's Republic of China; 4 Department of Kidney Transplantation, the Third Hospital of Sun Yat-Sen University, Guangzhou, People's Republic of China &astThese authors contributed equally to this work Correspondence: Jiansong Wang; Haifeng Wang, Department of Urology, the Second Affiliated Hospital of Kunming Medical University, Yunnan Institute of Urology, Kunming, 650101, People's Republic of China, Email ; Background: As known abnormal sialylation exerts crucial roles in the growth, metastasis, and immune evasion of cancers, but the molecular characteristics and roles in bladder cancer (BLCA) remain unclear. This study intends to establish BLCA risk stratification based on sialylation-related genes and elucidate its role in prognosis, tumor microenvironment, and immunotherapy of BLCA. Methods: Bulk RNA-seq and scRNA-seq data were downloaded from open-access databases. The scRNA-seq data were processed using the R package "Seurat" to identify the core cell types. The tumor sub-typing of BLCA samples was performed by the R package "ConsensusClusterPlus" in the bulk RNA-seq data. Signature genes were identified by the R package "limma" and univariate regression analysis to calculate risk scores using the R package "GSVA" and establish risk stratification of BLCA patients. Finally, the differences in clinicopathological characteristics, tumor microenvironment, and immunotherapy efficacy between the different groups were investigated. Results: 5 core cell types were identified in the scRNA-seq dataset, with monocytes and macrophages presenting the greatest percentage, sialylation-related gene expression, and sialylation scores. The bulk RNA-seq samples were classified into 3 tumor subtypes based on 19 prognosis-related sialylation genes. The 10 differential expressed genes (DEGs) with the smallest p-values were collected as signature genes, and the risk score was calculated, with the samples divided into high and low-risk score groups. The results showed that patients in the high-risk score group exhibited worse survival outcomes, higher tumor grade, more advanced stage, more frequency of gene mutations, higher expression levels of immune checkpoints, and lower immunotherapy response. Conclusion: We established a novel risk stratification of BLCA from a glycomics perspective, which demonstrated good accuracy in determining the prognostic outcome, clinicopathological characteristics, immune microenvironment, and immunotherapy efficacy of patients, and we are proposing to apply it to direct the choice of clinical treatment options for patients. Keywords: bladder cancer, bulk RNA-seq, scRNA-seq, sialylation, tumor microenvironment, immunotherapy Bladder cancer (BLCA) is one of the most prevalent malignancies of the urinary system, with an estimated 573,000 new cases and 213,000 deaths worldwide in 2020. 1 Depending on the tissue type, it can be classified into urothelial and non-urothelial cancers, out of which urothelial cancer is the most frequent pathological type of BLCA, accounting for about 90%. 2 Upon the invasion depth, it can be divided into non-muscle invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC), and their ratio is about 3:1 in patients with BLCA at the first consultation. 3 Risk factors in developing BLCA include smoking, and exposure to cyclic chemicals, dyes, and paints. Despite the accelerated development of comprehensive treatment with multiple therapies in recent years, including surgery, chemotherapy, radiotherapy, and immunotherapy. However, the high recurrence rate and high infiltration of BLCA have resulted in a poor prognostic outcome of patients with a median survival of merely 14 months. 4 Thus, a more in-depth investigation of the underlying mechanisms of BLCA is required to unlock new openings and identify more sensitive biomarkers for early diagnosis, individualized treatment, and prognostic outcomes of BLCA patients. The aberrant salivary acidif -Abstract Truncated-
immunology